



August 7, 2025

To whom it may concern

Company: SUNDRUG CO., LTD.  
Representative: Hiroshi Sadakata,  
CEO and Representative Director  
(Code number: 9989; Tokyo Stock Exchange, Prime Market)  
Contact: Yoshinobu Kato,  
Executive Officer and General Manager,  
Administrative Division  
TEL: +81-42-369-6211

### **Notice Regarding Receipt of Dividends from Consolidated Subsidiaries**

SUNDRUG CO., LTD. (the “Company”) has received dividends from its consolidated subsidiaries. As this matter falls under the requirements for filing an extraordinary report under Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 12 of the Cabinet Office Order on Disclosure of Corporate Affairs, the Company hereby announces the details thereof as below.

#### **1. Outline of the dividends**

- (1) Dividend amount: 6,176 million yen
- (2) Date of dividend receipt: June 23, 2025 and June 30, 2025
- (3) Dividend payout companies: Two consolidated subsidiaries of the Company  
(DIREX CORPORATION and SEIKODO PHARMACY CO., LTD.)

#### **2. Impact on business performance**

The Company recorded the dividend income above as non-operating income in its non-consolidated financial results for the fiscal year ending March 31, 2026. As the dividends are from its consolidated subsidiaries, there will be no impact on the Company’s consolidated financial results for the fiscal year ending March 31, 2026.